businesspress24.com - AVI BioPharma to Present Company Overview at the Wedbush Securities Life Science Conference
 

AVI BioPharma to Present Company Overview at the Wedbush Securities Life Science Conference

ID: 1029210

Webcast Accessible via AVI Website

(firmenpresse) - BOTHELL, WA -- (Marketwire) -- 08/10/11 -- AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, announced today that the company is scheduled to present at the Wedbush Securities Life Science Conference in New York City on Wednesday, August 17, at 9:10 a.m. Eastern Time. Chris Garabedian, AVI's president and CEO, will provide a company overview.

The presentation will be Webcast live under the events section of AVI's website at and will be archived there following the presentation for 90 days. Please connect to AVI's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

AVI BioPharma is focused on the discovery and development of novel RNA-based therapeutics for rare and infectious diseases, as well as other select disease targets. Applying pioneering technologies developed and optimized by AVI, the Company is able to target a broad range of diseases and disorders through distinct RNA-based mechanisms of action. Unlike other RNA-based approaches, AVI's technologies can be used to directly target both messenger RNA (mRNA) and precursor messenger RNA (pre-mRNA) to either down-regulate (inhibit) or up-regulate (promote) the expression of targeted genes or proteins. By leveraging its highly differentiated RNA-based technology platform, AVI has built a pipeline of potentially transformative therapeutic agents, including eteplirsen, which is in clinical development for the treatment of Duchenne muscular dystrophy, and multiple drug candidates that are in clinical development for the treatment of infectious diseases. For more information, visit .



AVI Investor and Media Contact:
David Schull
Russo Partners
858.717.2310 or 212.845.4271




Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Paladin Labs Announces Premium Offer to Acquire Afexa Life Sciences for $0.55 per Share
Marina Biotech Demonstrates In Vivo Knockdown of a microRNA With a CRN-Modified Antagomir
Bereitgestellt von Benutzer: MARKET WIRE
Datum: 10.08.2011 - 06:00 Uhr
Sprache: Deutsch
News-ID 1029210
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

BOTHELL, WA


Phone:

Kategorie:

Biotech


Anmerkungen:


Diese Pressemitteilung wurde bisher 188 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"AVI BioPharma to Present Company Overview at the Wedbush Securities Life Science Conference
"
steht unter der journalistisch-redaktionellen Verantwortung von

AVI BioPharma, Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von AVI BioPharma, Inc.



 

Who is online

All members: 10 563
Register today: 0
Register yesterday: 2
Members online: 0
Guests online: 60


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.